11/12
04:12 pm
beam
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference [Yahoo! Finance]
11/12
04:01 pm
beam
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
Low
Report
Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
11/7
02:28 pm
beam
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch [Seeking Alpha]
Low
Report
Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch [Seeking Alpha]
11/7
08:36 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
11/7
06:28 am
beam
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink [Yahoo! Finance]
Low
Report
Beam Therapeutics upgraded to Outperform from Market Perform at Leerink [Yahoo! Finance]
11/7
06:22 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
11/6
01:26 pm
beam
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
Low
Report
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates [Yahoo! Finance]
11/6
11:05 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target lowered by analysts at Royal Bank of Canada from $27.00 to $24.00. They now have a "sector perform" rating on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target lowered by analysts at Royal Bank of Canada from $27.00 to $24.00. They now have a "sector perform" rating on the stock.
11/6
08:05 am
beam
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
Medium
Report
Beam Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]
11/6
07:32 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $39.00 price target on the stock, up previously from $27.00.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $39.00 price target on the stock, up previously from $27.00.
11/6
02:22 am
beam
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... [Yahoo! Finance]
High
Report
Beam Therapeutics Inc (BEAM) Q3 2024 Earnings Call Highlights: Promising BEACON Trial Results ... [Yahoo! Finance]
11/5
06:24 pm
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
High
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $57.00 price target on the stock.
11/5
09:02 am
beam
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
Medium
Report
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates [Yahoo! Finance]
11/5
09:00 am
beam
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
High
Report
Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
11/5
06:36 am
beam
Beam Therapeutics GAAP EPS of -$1.17 misses by $0.02, revenue of $14.27M beats by $0.14M [Seeking Alpha]
Low
Report
Beam Therapeutics GAAP EPS of -$1.17 misses by $0.02, revenue of $14.27M beats by $0.14M [Seeking Alpha]
11/5
06:30 am
beam
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Low
Report
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
10/29
06:30 am
beam
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
Low
Report
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting
10/28
08:09 am
beam
We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow [Yahoo! Finance]
Low
Report
We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow [Yahoo! Finance]
10/16
08:44 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) is now covered by analysts at Scotiabank. They set a "sector outperform" rating on the stock.
9/19
09:21 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock.
Low
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $27.00 price target on the stock.
9/11
08:02 am
beam
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Stifel Nicolaus from $66.00 to $69.00. They now have a "buy" rating on the stock.
Medium
Report
Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Stifel Nicolaus from $66.00 to $69.00. They now have a "buy" rating on the stock.
9/10
11:39 am
beam
Glycogen Storage Disease Type 1a (GSD-1a) Treatment and Market Landscape Report 2024 [Yahoo! Finance]
Low
Report
Glycogen Storage Disease Type 1a (GSD-1a) Treatment and Market Landscape Report 2024 [Yahoo! Finance]
9/5
12:54 pm
beam
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? [Yahoo! Finance]